Brief Report
No access
Published Online: 24 August 2009

Omega 3 Fatty Acid Treatment in Autism

Publication: Journal of Child and Adolescent Psychopharmacology
Volume 19, Issue Number 4

Abstract

Objective: The purpose of this study was to determine the efficacy and safety of omega-3 fatty acids for children with autistic spectrum disorder (ASD).
Methods: This was an open-label pilot study. Ten children aged 4–7 years old with ASD according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), were given 1 gram daily of omega-3 fatty acids for 12 weeks. The main outcome measure used was the Autism Treatment Evaluation Checklist (ATEC). These data were collected between July, 2006, and June, 2007.
Results: Of the 9 subjects who completed the study, 8 showed improvement of about 33% on the Autism Treatment Evaluation Checklist (ATEC). None worsened and no side effects were reported.
Conclusions: Omega-3 fatty acids appear to be safe and might be helpful for children suffering from ASD. Further study is needed with a larger number of children in a double-blind design and with various doses of omega-3 fatty acids.

Get full access to this article

View all available purchase options and get full access to this article.

References

American Psychiatric Association: Manual of Diagnostic and Statistical Manual of Mental Disorders4th edition (DSM-IV)Washington (DC)American Psychiatric Association1994. American Psychiatric Association: Manual of Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington (DC): American Psychiatric Association, 1994.
Amminger GPBerger GESchafer MRKlier CFriedrich MHFeucht M. Omega-3 fatty acids supplementation in children with autism: A double-blind randomized, placebo-controlled pilot studyBiol Psychiatry22222006. Amminger GP, Berger GE, Schafer MR, Klier C, Friedrich MH, Feucht M: Omega-3 fatty acids supplementation in children with autism: A double-blind randomized, placebo-controlled pilot study. Biol Psychiatry 22:22, 2006.
Findling RLMcNamara NKGracious BLO'Riordan MAReed MDDemeter CBlumer GL. Quetiapine in nine youths with autistic disorderJ Child Adolesc Psychopharmacol14287-2942004. Findling RL, McNamara NK, Gracious BL, O'Riordan MA, Reed MD, Demeter C Blumer GL. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 14: 287–294, 2004.
Gagliano AGermano EPustorino GImpallomeni CD'Arrigo CCalamoneri F et al. Risperidone treatment of children with autistic disorder: Effectiveness, tolerability, and pharmacokinetic implicationsJ Child Adolesc Psychopharmacol1439-472004. Gagliano A, Germano E, Pustorino G, Impallomeni C, D'Arrigo C, Calamoneri F et al.: Risperidone treatment of children with autistic disorder: Effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 14:39–47, 2004.
Jarusiewicz B. Efficacy of neurofeedback for children in the autism spectrum: A pilot studyJ Neurother639-492002. Jarusiewicz B: Efficacy of neurofeedback for children in the autism spectrum: A pilot study. J Neurother 6:39–49, 2002.
Johnson SMHollander E. Evidence that eicosapentaenoic acid is effective in treating autismJ Clin Psychiatry64848-8492003. Johnson SM, Hollander E: Evidence that eicosapentaenoic acid is effective in treating autism. J Clin Psychiatry 64: 848–849, 2003.
Klaveness JBigam J. The GFCFKids Diet Survey—Preliminary resultshttp://www.gfcfdiet.com/dietsurveysept2.htm/2005. Klaveness J, Bigam J: The GFCFKids Diet Survey—Preliminary results. Accessed at http://www.gfcfdiet.com/dietsurveysept2.htm/, 2005.
Levant BRadel JDCarlson SE. Reduced brain DHA content after a single reproductive cycle in female rats fed a diet deficient in N-3 polyunsaturated fatty acidsBiol Psychiatry60987-9902006. Levant B, Radel JD, Carlson SE: Reduced brain DHA content after a single reproductive cycle in female rats fed a diet deficient in N-3 polyunsaturated fatty acids. Biol Psychiatry 60:987–990, 2006.
Lonsdale DShamberger RJAudhya T. Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: A pilot studyNeuro Endocrinol Lett23303-3082002. Lonsdale D, Shamberger RJ, Audhya T: Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: A pilot study. Neuro Endocrinol Lett 23:303–308, 2002.
451
Masi GCosenza AMucci MBrovedani P. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidoneJ Clin Psychiatry641039-10472003. Masi G, Cosenza A, Mucci M, Brovedani P: A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 64: 1039–1047, 2003.
Nemets HNemets BApter ABracha ZBelmaker RH. Omega-3 treatment of childhood depression: A controlled, double-blind pilot studyAm J Psychiatry1631098-11002006. Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH: Omega-3 treatment of childhood depression: A controlled, double-blind pilot study. Am J Psychiatry 163:1098–1100, 2006.
Overall JECampbell M. Behavioral assessment of psychopathology in children: Infantile autismJ Clin Psychol44708-7161988. Overall JE, Campbell M: Behavioral assessment of psychopathology in children: Infantile autism. J Clin Psychol 44: 708–716, 1988.
Peet MHorrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugsArch Gen Psychiatry59913-9192002. Peet M, Horrobin DF: A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 59:913–919, 2002.
Rimland BEdelson SM. Autism treatment checklist (ATEC)http://www.autism.com/ari/1999. Rimland B, Edelson SM: Autism treatment checklist (ATEC). Accessed at http://www.autism.com/ari/, 1999.
Salem N Jr.Litman BKim HYGawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous systemLipids36945-9592001. Salem N, Jr., Litman B, Kim HY, Gawrisch K: Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36:945–959, 2001.
Stella JMundy PTuchman R. Social and nonsocial factors in the Childhood Autism Rating ScaleJ Autism Dev Disord29307-3171999. Stella J, Mundy P, Tuchman R: Social and nonsocial factors in the Childhood Autism Rating Scale. J Autism Dev Disord 29: 307–317, 1999.
Stoll ALSeverus WEFreeman MPRueter SZboyan HADiamond E et al. Omega 3 fatty acids in bipolar disorder: A preliminary double-blind, placebo-controlled trialArch Gen Psychiatry56407-4121999. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E et al.: Omega 3 fatty acids in bipolar disorder: A preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 56: 407–412, 1999.
Vancassel SDurand GBarthelemy CLejeune BMartineau JGuilloteau D et al. Plasma fatty acid levels in autistic childrenProstaglandins Leukot Essent Fatty Acids651-72001. Vancassel S, Durand G, Barthelemy C, Lejeune B, Martineau J, Guilloteau D et al.: Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids 65:1–7, 2001.

Information & Authors

Information

Published In

cover image Journal of Child and Adolescent Psychopharmacology
Journal of Child and Adolescent Psychopharmacology
Volume 19Issue Number 4August 2009
Pages: 449 - 451
PubMed: 19702497

History

Published online: 24 August 2009
Published in print: August 2009

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Gal Meiri
Soroka University Medical Center, Beersheba, Israel.
Yoav Bichovsky
Soroka University Medical Center, Beersheba, Israel.
R.H. Belmaker
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel.

Notes

Address correspondence to:
R.H. Belmaker, M.D.
Beersheba Mental Health Center
PO Box 4600
Beer-Sheba,
Israel
E-mail: [email protected]

Disclosures

G. Meiri, Y. Bichovsky, and R.H. Belmaker have no conflicts of interest or financial ties to report.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top